Increased survival in hepatitis c patients who underwent living donor liver transplant: A case-control study with propensity score matching

Purpose: There is no consensus regarding the difference in outcomes of HCV in patients who receive living donor liver transplantation (LDLT) or compared to deceased donor liver transplantation (DDLT). The aims of this study were to compare characteristics between LDLT and DDLT groups and to identify risk factors affecting patient survival. Methods: We retrospectively reviewed the multicenter records of 192 HCV RNA-positive patients who underwent liver transplantation. Results: Thirty-five patients underwent DDLT, and 146 underwent LDLT. The 1-, 3-, and 5-year patient survival rates were 66.7%, 63.0%, and 63.0% in the DDLT group and 86.1%, 82.3%, and 79.5% in the LDLT group (P = 0.024), respectively. After propensity matching, the patient survival curve of the LDLT group was higher than that of the DDLT group. However, there was no statistically significant difference in patient survival between the 2 groups (P = 0.061). Recipient age ≥ 60 years LDLT, and use of tacrolimus were positively associated with patient survival in multivariate analyses. Conclusion: LDLT appears to be suitable for HCV-infected patients if appropriate living donor is available.